Associated tags: Genetics, Algorithm, Molina Healthcare, PRS, Medical device, Disease, Pharmaceutical industry, Fortis Healthcare, Laboratory, Precision medicine, Medicine, Coronary artery disease, Genomics, Genome, Patient, Cardiovascular disease
Locations: NEW YORK, BAYLOR, US
WGS,
Health informatics,
Informatics,
Coronary artery disease,
Associate,
Patient,
PRS,
ASHG,
Human genetics,
Laboratory,
Whole genome sequencing,
Baylor College of Medicine,
Society,
Traction,
BCM,
Physician,
Health NEW YORK, March 19, 2024 /PRNewswire/ -- Allelica, market leader in clinical solutions for polygenic risk score analysis and reporting, has announced a strategic collaboration with leading health sciences institution, Baylor College of Medicine (BCM), to integrate clinical, multi-ancestry polygenic risk score (PRS) testing into BCM's extensive patient services portfolio.
Key Points:
- NEW YORK, March 19, 2024 /PRNewswire/ -- Allelica, market leader in clinical solutions for polygenic risk score analysis and reporting, has announced a strategic collaboration with leading health sciences institution, Baylor College of Medicine (BCM), to integrate clinical, multi-ancestry polygenic risk score (PRS) testing into BCM's extensive patient services portfolio.
- This marks a significant milestone in making world class genomic medicine accessible, equitable, and impactful for patients across diverse communities.
- Allelica's PRS solution enables more precise identification of patients' genetic risk for coronary artery disease and other diseases and traits.
- Baylor is one of several institutions working with Allelica to provide clinical PRS testing to patients.
Retrieved on:
Thursday, November 9, 2023
PRS,
Laboratory,
United Kingdom,
CAD,
Genetic testing,
Genetics,
CAP,
Coronary artery disease,
Research,
CLIA,
Genomics,
Disease,
Risk,
Nature Communications,
LDL,
Medicine,
Partnership,
Patient,
Cardiovascular disease,
Pharmaceutical industry,
Medical device NEW YORK, Nov. 9, 2023 /PRNewswire/ --Allelica, a leading provider of clinical bioinformatics technology, has announced its scientific team's publication of their latest research in Nature Communications. The publication, "Ancestry-specific polygenic risk scores are risk enhancers for clinical cardiovascular disease assessments", builds on the company's ongoing efforts to make polygenic risk scores (PRSs) for coronary artery disease (CAD) accessible in healthcare settings for individuals of all ancestries. This research marks a significant milestone in Allelica's mission to revolutionize healthcare by harnessing the power of PRS.
Key Points:
- The publication, "Ancestry-specific polygenic risk scores are risk enhancers for clinical cardiovascular disease assessments", builds on the company's ongoing efforts to make polygenic risk scores (PRSs) for coronary artery disease (CAD) accessible in healthcare settings for individuals of all ancestries.
- Key findings of the publication include:
Allelica's CAD PRSs identify individuals at high genetic risk of disease across all major genetic ancestry groups.
- Using high CAD PRS as a risk factor leads to more accurate clinical risk assessments compared to models that don't use genetic information.
- Our results highlight the transformative potential of polygenic risk scores to identify this risk and use it in clinical risk assessments for one of the most common, and preventable diseases - coronary artery disease.
PDF,
APS,
PRS,
Laboratory,
American Society of Human Genetics,
CSO,
Clinical Laboratory,
Genetics,
Society,
CLIA,
Medicine,
Human genetics,
Medical device,
Internet service provider NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Allelica, the leading provider of software tools for clinical bioinformatics, announced the launch of its latest innovation, the Allelica Precision Server (APS). APS revolutionizes the way medical laboratories approach clinical bioinformatics analyses, streamlining polygenic risk score (PRS), pharmacogenomics (PGx), and carrier screening analyses securely and efficiently within their own environments.
Key Points:
- Allelica announces the release of the Allelica Precision Server for CLIA-compliant, on-premises analysis and clinical reporting of polygenic risk score, pharmacogenomics and carrier screening
NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Allelica, the leading provider of software tools for clinical bioinformatics, announced the launch of its latest innovation, the Allelica Precision Server (APS).
- APS revolutionizes the way medical laboratories approach clinical bioinformatics analyses, streamlining polygenic risk score (PRS), pharmacogenomics (PGx), and carrier screening analyses securely and efficiently within their own environments.
- APS is designed to support the development of clinical tests that meet the Clinical Laboratory Improvement Amendments (CLIA) standards, ensuring the accuracy and reliability of results.
- For clinical laboratories developing these tests, it's crucial to perform validation procedures using the same software tools which will be used in production.
Retrieved on:
Wednesday, February 22, 2023
Initiative,
Federated,
Woman,
Laboratory,
AUC,
Personalized medicine,
OR,
Medicine,
Cancer,
PRS,
Breast cancer,
Patient,
SD,
WGS,
Calibration,
Genetics,
Hasselt,
Module,
Coronary artery disease,
Version 2.0,
Whole genome sequencing,
SP,
Heart,
Chronic kidney disease,
Conditional sentence,
Cardiovascular disease,
Birth control,
Pharmaceutical industry NEW YORK, Feb. 22, 2023 /PRNewswire/ -- Allelica, the leading provider of polygenic risk score analysis technology, announced that it has joined forces with the Taiwanese precision medicine provider, SP BioMED, to perform a polygenic risk score (PRS) study for breast cancer. SP BioMED will run PRS analysis using Allelica's PREDICT module to calculate PRS for breast cancer on known breast cancer cases in their local biobanks.
Key Points:
- NEW YORK, Feb. 22, 2023 /PRNewswire/ -- Allelica, the leading provider of polygenic risk score analysis technology, announced that it has joined forces with the Taiwanese precision medicine provider, SP BioMED, to perform a polygenic risk score (PRS) study for breast cancer.
- SP BioMED will run PRS analysis using Allelica's PREDICT module to calculate PRS for breast cancer on known breast cancer cases in their local biobanks.
- "Breast cancer is the most common cause of cancer in Taiwanese women, so understanding the role that genetics plays in this disease risk is critical to identifying women at high risk," said Allelica CSO, George Busby.
- The breast cancer PRS calculated in the study is Allelica's proprietary PRS for breast cancer which has been clinically validated in multiple ancestries.
Retrieved on:
Tuesday, November 29, 2022
Birmingham,
Translation,
Radar,
Genetics,
Fortis Healthcare,
CAD,
University,
Multimedia,
Risk,
Clinic,
Genetic counseling,
Degenerative disease,
Physician,
Learning,
Cardiovascular disease,
Education,
Patient,
Risk assessment,
CLIA,
Death,
Disease,
Standard of care,
Precision medicine,
A Call for Unity,
Risk management,
PRS,
Infarction,
Coronary artery disease,
CAP,
UAB,
Algorithm,
Medical device NEW YORK, Nov. 29, 2022 /PRNewswire/ -- The UAB Cardiogenomics Clinic, led by Dr. Pankaj Arora, is partnering with the industry leader for polygenic risk score (PRS) analysis and reporting, Allelica Inc., to perform a clinical implementation study on PRS application for coronary artery disease. The aim of the study is to develop a clear path forward for the clinical implementation of PRS in cardiovascular disease prevention.
Key Points:
- The Cardiogenomics Clinic at the University of Alabama at Birmingham and Allelica are partnering to perform a clinical implementation study to assess how polygenic risk score integration changes clinical management and health outcomes in a US health system.
- NEW YORK, Nov. 29, 2022 /PRNewswire/ -- The UAB Cardiogenomics Clinic, led by Dr. Pankaj Arora, is partnering with the industry leader for polygenic risk score (PRS) analysis and reporting, Allelica Inc., to perform a clinical implementation study on PRS application for coronary artery disease.
- The aim of the study is to develop a clear path forward for the clinical implementation of PRS in cardiovascular disease prevention.
- The results of this study will help to establish a clear pathway for providers for the clinical implementation of PRS in cardiovascular disease risk management and prevention.
Retrieved on:
Wednesday, September 21, 2022
Health,
Precision medicine,
Laboratory,
Algorithm,
Saliva,
Risk,
Hospital,
LDT,
PRS,
Partnership,
Coronary artery disease,
Environment,
Diabetes,
Foundation,
Patient,
Type 2,
Degenerative disease,
Cancer,
Breast cancer,
Genetics,
Type 2 diabetes,
CEO,
Solution,
CAP,
Life,
Fortis Healthcare,
Polygene,
Cardiology,
Food,
Pharmacology,
Harvard Medical School,
Genomics,
DNA,
Prostate cancer,
Medicine,
Multimedia,
Cone Health Women's Hospital,
Genome,
Disease,
Alzheimer's disease,
Brigham and Women's Hospital,
Microarray,
Pharmaceutical industry,
Medical device,
Online shopping,
Brigham,
Eurofins Scientific NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Allelica, a leading genomics software company that provides digital tools for the development, validation and calculation of ancestry-specific polygenic risk scores (PRSs), announced that PRS analysis is now available as a laboratory-developed test (LDT) for healthcare providers looking to improve health outcomes. The test is made possible through a partnership with Clinical Enterprise Inc., a CLIA-certified, CAP-accredited laboratory located in Framingham, Mass.
Key Points:
- The test is made possible through a partnership with Clinical Enterprise Inc., a CLIA-certified, CAP-accredited laboratory located in Framingham, Mass.
- Allelica's new, ancestry-specific PRS tests are available as a physician-ordered test and set new standards for accessibility, accuracy, and cost.
- The tests use a patient's saliva as a DNA sample for genotyping analysis carried out by Clinical Enterprise.
- Allelica is a leading genomic software company that specializes in secure and scalable solutions to implement clinical-grade polygenic risk scores (PRSs).
PRS,
CAD,
Journal of the American Heart Association,
CEO,
Journal,
Illumina, Inc.,
American Heart Association,
Stroke,
Industry,
Risk assessment,
Genetic testing,
PCE,
Profile,
Coronary artery disease,
Policy,
Risk,
University,
Standard of care,
Cardiovascular disease,
Health,
Degenerative disease,
Solution,
Markov,
Moyamoya disease,
Medical device,
Pharmaceutical industry NEW YORK, July 7, 2022 /PRNewswire/ -- Allelica, a leading genomic software company specializing in secure and scalable solutions to implement clinical-grade PRS, has published a health economics study in the Journal of the American Heart Association. The study's authors concluded that integrating PRS as an additional risk-enhancing factor in the Pooled Cohort Equation (PCE) risk assessment (the standard of care for determining the risk of atherosclerotic cardiovascular disease) is cost-saving for US healthcare systems.
Key Points:
- "The results of this study showed us that adding PRS to the standard of care not only improves individual health outcomes; it saves money.
- Allelica health economist Dr. Deo Mujwara led the study, in collaboration with experts from both industry and academia at Illumina Inc. and the University of Sydney.
- The risk of developing CAD, the effectiveness of statin prevention therapy, and the cost of treating CAD had the largest impact on the cost per qualityadjusted lifeyear gained.
- Allelica is a leading genomic software company that specializes in secure and scalable solutions to implement clinical-grade polygenic risk scores (PRSs).
CSO,
Woman,
NEW,
Algorithm,
NYSE,
Genome,
Breast cancer,
Partnership,
DNA,
Genomics,
Precision medicine,
Cancer,
Disease,
Genetics,
Solution,
Fortis Healthcare,
PRS,
Foundation,
Risk,
Multimedia,
Medical imaging,
Vaccine,
Medical device,
Invitae NEW YORK, May 3, 2022 /PRNewswire/ -- Allelica has formalized a partnership with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to build a clinical artificial intelligence architecture for breast cancer polygenic risk score (PRS) development and clinical implementation in multiple ancestries.
Key Points:
- Allelica and Invitae aim to decrease the gap in polygenic risk score (PRS) performance in individuals from diverse genetic ancestries, ensuring that the life-saving integration of genomic information into breast cancer risk assessments can benefit all women
NEW YORK, May 3, 2022 /PRNewswire/ -- Allelica has formalized a partnership with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to build a clinical artificial intelligence architecture for breast cancer polygenic risk score (PRS) development and clinical implementation in multiple ancestries.
- "We're eager to work together to provide tools that will ultimately reduce the impact of breast cancer for women of all ancestries."
- Allelica's collaboration with Invitae involves the development and validation of a new PRS for breast cancer and its integration with absolute risk models to estimate 10-year and lifetime risk in women of multiple ancestries.
- Polygenic factors and pathogenic variants in moderate- and high-risk genes account for similar proportions of the familial relative risk of breast cancer.
Solution,
Foundation,
CEO,
Algorithm,
Gene,
University of Michigan Solar Car Team,
Technology,
Laboratory,
Multimedia,
Precision medicine,
Research,
Doctor of Philosophy,
Genetics,
PRS,
Fortis Healthcare,
Genetic variation,
Risk,
Genomics,
Genome,
Health,
Disease,
Pharmaceutical industry,
Medical device,
Illumina NEW YORK, April 28, 2022 /PRNewswire/ -- Allelica, a leading genomics software company that develops digital tools to develop, validate and calculate PRS for common diseases, announced that Illumina, a leading developer and manufacturer of life-science tools and integrated systems for large-scale analysis of genetic variation, is licensing Allelica's software to provide its customers with cutting-edge polygenic risk score (PRS) capabilities.
Key Points:
- Allelica's platform streamlines the entire polygenic risk scoring process: genotype imputation, PRS development and validation in multiple ancestries for a range of diseases, and detailed reporting services.
- The collaboration also includes co-development of an Infinium Genotyping Array that includes expertly selected content specific for polygenic risk score predictions.
- Allelica is a leading genomic software company that specializes in secure and scalable solutions to implement clinical-grade polygenic risk scores (PRSs).
- Allelica's technology combines world-class datasets with the most advanced algorithms to build PRSs with the highest predictive power for estimating disease risk.
Risk,
Fortis Healthcare,
Yale School of Medicine,
Conditions comorbid to autism spectrum disorders,
NEW,
Tourette syndrome,
Multimedia,
Genetics,
Yale school,
Research,
CSO,
Genomics,
Autism,
PRS,
Anxiety,
Precision medicine,
MD,
Lists of diseases,
Genome,
Technology,
Foundation,
Genetic variation,
Gene,
Solution,
ADHD,
OCD,
Tic disorder,
Disease,
Algorithm,
Medical device,
Pharmaceutical industry,
Medicine NEW YORK , April 12, 2022 /PRNewswire/ -- Allelica, a leading genomics software company that develops digital tools to develop, validate and calculate polygenic risk scores for common diseases, is teaming with Thomas Fernandez, MD of Yale School of Medicine in a research project aimed at uncovering the genetic basis for multiple childhood neuropsychiatric disorders.
Key Points:
- Dr. Fernandez of Yale School of Medicine will use Allelica's PRS technology to better understand the genetic basis for multiple childhood neuropsychiatric disorders, including obsessive-compulsive disorder (OCD), ADHD, anxiety disorders, Tourette Syndrome, chronic tic disorders, motor stereotypies, and autism spectrum disorders.
- Dr. Fernandez will use Allelica's polygenic risk score (PRS) modules to accelerate his ongoing research determining the genetic basis for neuropsychiatric disorders such as obsessive-compulsive disorder (OCD), ADHD, anxiety disorders, Tourette Syndrome, chronic tic disorders, motor stereotypies, and autism-spectrum disorders.
- Dr. Fernandez aims to discover which combinations of genes are underlying risk factors for these disorders in individuals with varying polygenic backgrounds.
- "My lab is excited to expand our genetic investigations of childhood neuropsychiatric disorders using Allelica's tools," said Dr. Fernandez.
